AtriCure (Nasdaq:ATRC) announced today that it launched the EnCompass Clamp as part of its Isolator Synergy ablation system.
Mason, Ohio-based AtriCure received FDA 510(k) clearance for the EnCompass Clamp for the ablation of cardiac tissue during cardiac surgery to make concomitant surgical ablations more efficient.
According to a news release, the platform includes parallel closure, uniform pressure and custom power using Synergy radiofrequency (RF). AtriCure said the new features of the EnCompass Clamp allow for easier placement using a magnetic guide, enabling more efficient procedures by minimizing tissue dissection.
“The EnCompass Clamp provides a simpler and faster approach to ablating the heart in open-chest procedures,” AtriCure President and CEO Michael Carrel said in the release. “We are passionate about innovation, leading to high-quality options for our physician partners. We believe the EnCompass Clamp will meet the unique needs of surgeons who are performing closed-atrium cardiac surgery.”